Login to Your Account



Other News To Note


Thursday, October 10, 2013

• Catalyst Biosciences Inc., of South San Francisco, and Isu Abxis, a Korean biologics manufacturing and development company, formed a collaboration to develop Catalyst’s next-generation Factor IX development candidate, FIX-NG (CB 2679d), for the prevention and treatment of bleeding in hemophilia B patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription